Company Overview
Marker Therapeutics (MRKR) was formed in October 2017 with a merger of privately held company Marker Cell Therapy, Inc. and TapImmune. Marker is a clinical-stage biotechnology company specializing in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor.
Marker has formed a strategic partnership with the Cell and Gene Therapy Center at Baylor College of Medicine (“BCM”) whom they have partnered with for several product candidates. Marker has also formed a Scientific Advisory Board (“SAB”) with various prominent names